HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents, Hormonal
  • Breast Neoplasms
  • Receptor, ErbB-2
  • Receptors, Estrogen
  • Tamoxifen
  • Tumor Suppressor Protein p53

abstract

  • Disease-free and overall survival benefit of tamoxifen in patients with ER-positive, node-positive breast cancer does not depend on HER-2/neu or p53 status. Our data suggest that neither HER-2/neu nor p53 expression should be used to determine assignment of tamoxifen.

publication date

  • October 15, 2000

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 11032587

Additional Document Info

start page

  • 3471

end page

  • 9

volume

  • 18

number

  • 20